Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Spire Wealth Management increased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 393.3% during the 4th quarter, according to its most recent Form 13F ...

Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 11.71%, which has investors questioning if this is right ...

Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as its Chair Designate. Dr. Slaoui, a notable figure ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

SAN DIEGO, January 30, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...

Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...